GeneTether Therapeutics Inc. (CSE: GTTX)

GeneTether Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 29, 2024	Dec 30, 2023	Dec 30, 2022	Dec 30, 2021	Dec 30, 2020	Dec 30, 2019
Net Income	-0.7	-0.69	-1.72	-1.64	-0.07	-0.09
Stock-Based Compensation	0.27	0.18	0.62	0.88	0	-
Other Operating Activities	-0.01	-0.01	0	0	-	-
Change in Accounts Payable	-0	-0.05	-0.13	0.21	0	-0.01
Change in Other Net Operating Assets	0.04	0.1	0.04	-0.19	0	-0
Operating Cash Flow	-0.39	-0.46	-1.18	-0.74	-0.07	-0.1
Short-Term Debt Issued	-	-	-	-	0.1	0.04
Total Debt Issued	-	-	-	-	0.1	0.04
Net Debt Issued (Repaid)	-	-	-	-	0.1	0.04
Issuance of Common Stock	-	-	3	0.87	0	0.04
Financing Cash Flow	-	-	3	0.87	0.1	0.08
Foreign Exchange Rate Adjustments	-0	0.03	-0.2	-	-	-
Net Cash Flow	-0.4	-0.43	1.62	0.13	0.04	-0.02
Free Cash Flow	-0.39	-0.46	-1.18	-0.74	-0.07	-0.1
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.02	-0.00	-0.14
Levered Free Cash Flow	-0.16	-0.24	-0.54	-0.13	-0.04	-0.06
Unlevered Free Cash Flow	-0.16	-0.24	-0.54	-0.13	-0.04	-0.06
Change in Net Working Capital	-0.04	-0.05	0.08	-0.02	-0	0.01

Source: S&P Capital IQ. Standard template. Financial Sources.